10:55 AM EDT, 09/04/2024 (MT Newswires) -- iRhythm Technologies ( IRTC ) said Wednesday it has signed a license agreement with BioIntelliSense to create and commercialize pulse oximetry, accelerometry and non-invasive blood pressure technologies for iRhythm's ambulatory cardiac monitoring products and services.

Financial terms of the agreement weren't disclosed.

Additionally, iRhythm said it reaffirms the 2024 revenue outlook it reported in August and will update it when it posts its Q3 results.

Shares of the company were up 4.3% in recent Wednesday trading.

Price: 70.94, Change: +2.94, Percent Change: +4.32